MilliporeSigma plans to open distribution center in Visalia Industrial Park by the end of this year
By Reggie Ellis @Reggie_SGN
VISALIA – One of the world’s leaders in the research and development of pharmaceutical products and genetic editing will soon be part of the Visalia Industrial Park.
MilliporeSigma has confirmed it will be opening a 120,000-square foot distribution center in Visalia in the fourth quarter of this year. Karen Tiano, spokesperson for MilliporeSigma, said the company chose Visalia due to its central location and easy access to transportation routes. She said the Visalia facility will employ about 30 people to distribute the company’s products primarily throughout California.
“This will be a local distribution center for our California market capable of storing a range of products, including temperature sensitive products,” Tiano said in an email last week. “We serve a variety of West Coast customers that will benefit from this new distribution center.”
A leader in life science, MilliporeSigma develops and manufactures scientific lab materials, technologies, and services in the areas of pharmaceuticals, equipment and food and drug testing. MilliporeSigma is the parent company for six life science brands including Sigma-Aldrich, Milli-Q, Supelco, Millipore, BioReliance, and SAFC.
The company is a subsidiary of Merck KGaA, Darmstadt, Germany, an international pharmaceutical conglomerate specializing in science and technology across healthcare, life science and performance materials. Around 51,000 employees work for the company in cutting edge labs to advance gene-editing technologies and discover unique ways to treat the most challenging diseases to enabling the intelligence of devices. In 2017, Merck KGaA, Darmstadt, Germany—which operates in the U.S. as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials—generated billions in sales in 66 countries. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
MilliporeSigma has received awards for innovative products for the pharmaceutical industry and for research and development of technologies for analytical testing and genome editing. The company is a leader in the controversial field of genome editing. CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging — from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness. At the same time, the growing potential of genome-editing technologies has opened scientific, legal and societal concerns. MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma’s parent company, Merck, KGaA, Darmstadt, Germany, has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.
“We are committed to making our patented CRISPR technology broadly available to the global research and discovery community,” said Udit Batra, CEO, MilliporeSigma stated in an announcement in December. “We will continue to play an active role, responsibly and ethically, in ensuring that scientists have access to the latest CRISPR technologies.”
With a 14-year history in the genome-editing field, MilliporeSigma was the first company to offer custom biomolecules for genome editing globally, driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.